Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Buying Vetnex, Pfizer Invests $40 Million To Set Up Discovery Research Center For Animal Health Drugs In India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - When Pfizer's $3.5 billion animal health unit made a resolute bid last June to acquire Vetnex - a small but growing Indian veterinary care company - it took industry watchers by surprise, but a well-crafted, elaborate plan was stealthily being executed

You may also be interested in...



Pfizer Inks Animal Health JV With Chinese Company Jilin Guoyuan

Pfizer Inc. announced a joint venture Sept. 8 with China's Jilin Guoyuan Animal Heatlh Company, Ltd. to develop, manufacture and distribute animal health vaccines in China

Pfizer Inks Animal Health JV With Chinese Company Jilin Guoyuan

Pfizer Inc. announced a joint venture Sept. 8 with China's Jilin Guoyuan Animal Heatlh Company, Ltd. to develop, manufacture and distribute animal health vaccines in China

India's RFCL Braves Into The Stronghold Of MNCs With High-end Diagnostics; Will It Become The Next Takeover Candidate?

MUMBAI - Having identified a distinct cost advantage over its bigger Western counterparts, RFCL - India's largest in-vitro diagnostics and laboratory solutions firm - is branching out into the manufacture of high-end diagnostic products used for immunoassays, a range of molecular diagnostic kits and theranostics, bringing it a step closer toward personalized medicine

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel